- Therapeutic options for management of endometrial hyperplasia
-
Chandra V, Kim JJ, Benbrook D, Dwivedi A, Rai R
- KMID: 2360238
- J Gynecol Oncol.
- 2016 Jan;27(1):e8.
- doi: 10.3802/jgo.2016.27.e8
Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual... -
- CITED
-
- Close
- SHARE
-
- Close
- The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
-
Kim CS, Theeuwes A, Kwon DD, Choi YD, Chung BH, Lee HM, Lee KH, Lee SE
- KMID: 2426491
- Investig Clin Urol.
- 2016 May;57(3):174-183.
- doi: 10.4111/icu.2016.57.3.174
PURPOSE: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. MATERIALS AND METHODS: Asymptomatic or mildly symptomatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use
-
Kim SI, Lee Y, Son Y, Jun SY, Yun S, Bae HS, Lim MC, Jung SY, Joo J, Lee ES
- KMID: 2351110
- J Korean Med Sci.
- 2015 Nov;30(11):1604-1611.
- doi: 10.3346/jkms.2015.30.11.1604
Breast cancer is the most common type of female cancer. Tamoxifen, a selective estrogen receptor modulator, is widely used to decrease breast cancer recurrence and mortality among patients. However, it... -
- CITED
-
- Close
- SHARE
-
- Close
